These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 3162176)
41. [Treatment of carcinoma of the prostate with analogs of LHRH]. Rubio Herrera MA; Calle Fernández JR Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782 [No Abstract] [Full Text] [Related]
42. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents. Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J Prostate; 1986; 9(4):327-42. PubMed ID: 2947053 [TBL] [Abstract][Full Text] [Related]
43. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol]. Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071 [TBL] [Abstract][Full Text] [Related]
44. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone. Waxman JH; Wass JA; Hendry WF; Whitfield HN; Bary P; Besser GM; Malpas JS; Oliver RT Br J Urol; 1983 Dec; 55(6):737-42. PubMed ID: 6418264 [TBL] [Abstract][Full Text] [Related]
45. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals. Greil S; Robinson EA; Singal B; Kleer E Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301 [TBL] [Abstract][Full Text] [Related]
46. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524 [TBL] [Abstract][Full Text] [Related]
47. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin. Falkson CI; Falkson G; Falkson HC Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843 [TBL] [Abstract][Full Text] [Related]
48. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen]. Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527 [TBL] [Abstract][Full Text] [Related]
49. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study. Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408 [No Abstract] [Full Text] [Related]
50. The Japanese experience: use of transrectal ultrasound in the evaluation of tumor response to various treatment modalities. Watanabe H Prog Clin Biol Res; 1987; 237():195-208. PubMed ID: 3120200 [No Abstract] [Full Text] [Related]
51. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825 [TBL] [Abstract][Full Text] [Related]
52. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. Labrie F; Dupont A; Belanger A; Lachance R; Giguere M Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197 [TBL] [Abstract][Full Text] [Related]
53. [Testosterone in saliva: application to the follow-up of prostate cancer]. Navarro-Moreno MA; Rivera-Coll A Rev Esp Fisiol; 1990 Mar; 46(1):63-8. PubMed ID: 2204093 [TBL] [Abstract][Full Text] [Related]
54. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810 [TBL] [Abstract][Full Text] [Related]
55. Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. Eisenberger MA; O'Dwyer PJ; Friedman MA J Clin Oncol; 1986 Mar; 4(3):414-24. PubMed ID: 2936872 [TBL] [Abstract][Full Text] [Related]
56. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893 [TBL] [Abstract][Full Text] [Related]
57. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Klioze SS; Miller MF; Spiro TP Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455 [TBL] [Abstract][Full Text] [Related]
58. Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron). Dörner G; Schnorr D; Stahl F; Rohde W Exp Clin Endocrinol; 1985 Dec; 86(2):190-6. PubMed ID: 3912197 [TBL] [Abstract][Full Text] [Related]
59. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients]. Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389 [TBL] [Abstract][Full Text] [Related]
60. The first clinical use of depot buserelin for advanced prostatic carcinoma. Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]